In summary, our findings provide compelling evidence in support of tumor-suppressive properties of PTPRK and its prognostic significance in glioma along with discovery of several mutations leading to altered functionality of the PTPRK protein which subsequently affect therapeutics. The gene discussed is PTPRK; the disease is central nervous system cancer.